Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI
Table 1
Baseline characteristics of the study subjects.
Rosuvastatin (n = 90)
Ezetimibe/rosuvastatin (n = 81)
value
Male, n (%)
63 (70.0%)
55 (67.9%)
0.77
Age (years)
64.08 ± 10.45
61.74 ± 8.78
0.12
BMI (kg/m2)
24.36 ± 3.18
24.24 ± 3.49
0.82
Current smokers, n (%)
44 (48.9%)
34 (42.0%)
0.37
Diabetes mellitus, n (%)
30 (33.3)
29 (35.8)
0.74
Hypertension, n (%)
50 (55.5)
41 (50.6)
0.52
Dyslipidemia, n (%)
37 (41.1)
23 (28.4)
0.08
LVEF (%)
59.00 ± 7.47
60.17 ± 7.87
0.32
Presentation of ACS
STEMI, n (%)
24 (26.7)
16 (19.8)
0.29
NSTEMI, n (%)
13 (14.4)
6 (7.4)
0.14
UA, n (%)
53 (58.9)
59 (72.8)
0.06
Previous medications
Aspirin, n (%)
10 (11.1)
7 (8.6)
0.59
Clopidogrel, n (%)
5 (5.6)
3 (3.7)
0.57
Beta-blockers, n (%)
10 (11.1)
5 (6.2)
0.25
ACE inhibitors, n (%)
14 (15.6)
9 (11.1)
0.40
Values are presented as n (%) or mean ± standard deviation. BMI, body mass index; LVEF, left ventricular ejection fraction; ACS, acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, none ST-segment elevation myocardial infarction; UA, unstable angina; ACE, angiotensin-converting enzyme.
